RxDoctor Payments Data

Margaret Ekroth, MD

Urology · Iowa City, IANPI 1215106851

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $1,925 of the $2,998 with a category attached, or 64.2%. 20 manufacturers reported payments, led by Boston Scientific at 38.4% of the total. 2025 is the largest year on record at $1,151, 2.4 times the $482 reported in 2019.

$2,998in general payments, 2019–2025

Across 103 payments — averaging $29.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$1K
  • Johnson & Johnson$343
  • 180 Medical, Inc.$237
  • Pfizer$217
  • Astellas Pharma US Inc$181
  • Axonics, Inc.$138
  • plus $732 from 14 others

What the payments were for

  • Travel & lodging$91030%
  • Food & beverage$1,92564%
  • Education$1635%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,998 in reported general payments places this provider in the 60th percentile of 114 urology providers in Iowa.

See all urology providers in Iowa

Medicare billing

Part B allowed, 2024
$205,406
Medicare patients
421
Services billed
5,638

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide11$160,453
MyrbetriqMirabegron76$40,898
Potassium Citrate ErPotassium Citrate53$6,953
Estradiol89$6,689
Tamsulosin Hcl344$6,635
Finasteride295$4,202
Oxybutynin Chloride ErOxybutynin Chloride102$2,253
Fesoterodine Fumarate ErFesoterodine Fumarate14$2,164
NitrofurantoinNitrofurantoin Macrocrystal47$1,161
Trimethoprim12$579
Cephalexin134$502
Silodosin12$345
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst17$261
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim26$84
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav17$84

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$343$160,45311 claims
Astellas Pharma US IncMyrbetriq$181$40,89876 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 114 urology providers in Iowa.

Other urology in Iowa City

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →